Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
4.800
+0.160 (3.45%)
May 29, 2026, 4:00 PM EDT - Market closed
MRVI Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 165.92 | 216.89 | 322.4 | 574.96 | 632.14 | 551.27 |
Cash & Short-Term Investments | 165.92 | 216.89 | 322.4 | 574.96 | 632.14 | 551.27 |
Cash Growth | -41.79% | -32.73% | -43.93% | -9.04% | 14.67% | 133.41% |
Accounts Receivable | 33.42 | 25.5 | 38.52 | 54.61 | 138.62 | 117.51 |
Other Receivables | - | - | - | - | 8.19 | - |
Total Trade Receivables | 33.42 | 25.5 | 38.52 | 54.61 | 146.81 | 117.51 |
Inventory | 40.46 | 40.5 | 50.08 | 51.4 | 43.15 | 51.56 |
Other Current Assets | 11.94 | 13.37 | 18.15 | 18.95 | 25.8 | 19.7 |
Total Current Assets | 251.74 | 296.25 | 429.15 | 699.91 | 847.9 | 740.04 |
Net Property, Plant & Equipment | 146.93 | 151.48 | 164.47 | 162.9 | 52.69 | 46.33 |
Other Intangible Assets | 144.89 | 151.54 | 194.96 | 220.99 | 216.66 | 117.57 |
Goodwill | 129.43 | 129.43 | 159.88 | 326.03 | 283.67 | 152.77 |
Other Long-Term Assets | 40.24 | 41.88 | 59.79 | 77.62 | 881.39 | 861.57 |
Total Assets | 713.22 | 770.58 | 1,008 | 1,487 | 2,282 | 1,918 |
Accounts Payable | 8.54 | 2.91 | 11.96 | 10.73 | 5.99 | 8.15 |
Accrued Expenses | 28.65 | 36.57 | 39.57 | 60.24 | 53.37 | 34.57 |
Current Portion of Long-Term Debt | 5.44 | 5.44 | 5.44 | 5.44 | 5.44 | 6 |
Current Portion of Leases | - | - | - | 0.63 | - | - |
Unearned Revenue | - | - | - | 3.36 | 3.09 | 10.21 |
Other Current Liabilities | - | - | - | 7.07 | 42.25 | 34.84 |
Total Current Liabilities | 42.62 | 44.92 | 56.97 | 87.47 | 110.14 | 93.78 |
Long-Term Debt | 235.57 | 286.33 | 290.49 | 518.71 | 522 | 524.59 |
Long-Term Leases | 29.87 | 30.14 | 31.11 | 31.9 | - | - |
Other Long-Term Liabilities | 36.07 | 36.48 | 52.47 | 59.49 | 744.93 | 754.55 |
Total Long-Term Liabilities | 301.51 | 352.95 | 374.06 | 610.1 | 1,267 | 1,279 |
Total Liabilities | 344.13 | 397.87 | 431.04 | 697.57 | 1,377 | 1,373 |
Common Stock | 2.58 | 2.56 | 2.53 | 2.51 | 2.55 | 2.55 |
Additional Paid-in Capital | 202.13 | 199.18 | 181.87 | 128.5 | 137.9 | 128.39 |
Accumulated Other Comprehensive Income | 0.47 | 0.52 | - | - | - | - |
Retained Earnings | 6.39 | 10.12 | 140.89 | 285.74 | 404.77 | 184.56 |
Total Common Shareholders' Equity | 211.56 | 212.38 | 325.29 | 416.75 | 545.22 | 315.5 |
Minority Interest | 157.52 | 160.33 | 251.92 | 373.13 | 360.03 | 229.86 |
Shareholders' Equity | 369.08 | 372.71 | 577.21 | 789.88 | 905.24 | 545.36 |
Total Liabilities & Equity | 713.22 | 770.58 | 1,008 | 1,487 | 2,282 | 1,918 |
Total Debt | 270.88 | 321.91 | 327.04 | 556.68 | 527.44 | 530.59 |
Net Cash (Debt) | -104.96 | -105.02 | -4.64 | 18.29 | 104.7 | 20.68 |
Net Cash Growth | - | - | - | -82.54% | 406.27% | - |
Net Cash Per Share | -0.71 | -0.73 | -0.03 | 0.14 | 0.41 | 0.08 |
Book Value | 211.56 | 212.38 | 325.29 | 416.75 | 545.22 | 315.5 |
Book Value Per Share | 1.44 | 1.47 | 2.36 | 3.16 | 2.14 | 1.22 |
Tangible Book Value | -62.75 | -68.59 | -29.54 | -130.26 | 44.89 | 45.16 |
Tangible Book Value Per Share | -0.43 | -0.48 | -0.21 | -0.99 | 0.18 | 0.18 |